TCRX (TScan Therapeutics) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRX TScan Therapeutics Inc TCRX
44 GF Score
Price $0.73
GF Value $1.32
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is TScan Therapeutics SpecialCharges?

Special Charges only applies to banks.

TCRX
44GF Score
TScan Therapeutics Inc TCRX
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TScan Therapeutics (TCRX) Overvalued in 2026?

Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued. The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32. GuruFocus considers TScan Therapeutics to be Possible Value Trap.

Key valuation signals for TCRX:

  • SpecialCharges:
  • GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TScan Therapeutics Business Description

Address 830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score

Get the complete analysis for TCRX

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price
$1.32
GF Value